Smart science to improve lives™
Open search Basket 0 View basket

Specializing in specific enhancement technologies

Croda Pharma specializes in four technologies aimed at improving bioavailability and solubility. First, nanoparticle-based delivery systems such as liposomes, nanoemulsions, and inorganic nanoparticles, offer large surface area to encapsulate drugs that further improves their solubility and bioavailability.1 These systems can also protect active pharmaceutical ingredients from degradation and offer a targeted delivery. Additionally, there is reduction in toxicity, greater safety, and biocompatibility.2 A tool that has recently emerged for the development of nano systems like solid lipid nanocarriers, nanoemulsions, liposomes etc. is microfluidic technology, which provides enhanced precision, efficiency and functionality3, says Kritika Bajaj, PhD, Research Scientist at Croda Pharma. 

Second, self-emulsifying drug delivery systems (SEDDS) and self-microemulsifying drug delivery systems (SMEDDS) are formulations consisting of oils, surfactants, solvents, and drug substance. They spontaneously form oil-in-water emulsions when introduced to aqueous phase. These systems enable improvement in oral bioavailability of a poorly water-soluble drug.4 These systems are easy to make, economical, and scalable, says Dr. Bajaj. 

Third, amorphous solid dispersion (ASD) technology involves utilizing excipients to assist in dispersing a poorly soluble drug in a hydrophilic inert carrier matrix (usually a polymer) to enhance its solubility and dissolution rate upon administration. This technology works by increasing surface area, improving wettability, tailoring release profiles, and enhancing solubility by dispersing a drug in an amorphous state. 

Finally, a permeation enhancer works by improving the transport of poorly absorbed actives across biological barriers such as skin, mucosa, or gastrointestinal tract. They can aid transdermal and oral drug delivery.5,6 Compounds such as surfactants, dimethyl isosorbide (DMI), and lipid-based excipients can improve drug permeability across biological barriers, leading to increased bioavailability.7 

Dr. Bajaj says: “For the technologies discussed above, Croda’s portfolio of high purity excipients used as surfactants, permeation enhancers, polymers, lipids, and oils can play a significant role in the above-mentioned technologies to enable improved solubility and bioavailability of drugs.” 

Explore recent blogs:

manufacturing pd

QbD Formulation Development

Formulation development is a pivotal stage in the life cycle of a therapeutic drug product, it can be the make or break of it. The goal of formulation development is to convert active substance (drug...
green washed depiction of an LNP

Targeted lipid nanoparticles in Nucleic Acid Delivery

Targeted lipid nanoparticles (tLNPs) enhance the precision and efficacy of delivering a variety of therapeutic agents including nucleic acids to specific tissues and cell populations, thereby...
Blue washed image of female in the lab

Croda joins CGT Catapult consortium to improve AAV formulation

The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation.
man in a lab looking at results

Synthesis, characterisation and degradation of polysorbates in biopharmaceuticals

Polysorbates are essential in biologics delivery, serving as crucial emulsifiers and stabilisers for biopharmaceuticals. They enhance solubility, improve bioavailability, and protect proteins from...
(1) Patra, J. K.; Das, G.; Fraceto, L. F.; Campos, E. V. R.; Rodriguez-Torres, M. d. P.; Acosta-Torres, L. S.; Diaz-Torres, L. A.; Grillo, R.; Swamy, M. K.; Sharma, S.; et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology 2018, 16 (1), 71. 10.1186/s12951-018-0392-8
(2) De Jong, W. H.; Borm, P. J. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 2008, 3 (2), 133-149. 10.2147/ijn.s596
(3) Rawas-Qalaji, M.; Cagliani, R.; Al-Hashimi, N.; Al-Dabbagh, R.; Al-Dabbagh, A.; Hussain, Z. Microfluidics in drug delivery: review of methods and applications. Pharm Dev Technol 2023, 28 (1), 61-77. 10.1080/10837450.2022.2162543
(4) Pharma, C. SEDDS and SMEDDS.,aqueous%20phases%20under%20gentle%20agitation.
(5) Kováčik, A.; Kopečná, M.; Vávrová, K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Expert Opin Drug Deliv 2020, 17 (2), 145-155. 10.1080/17425247.2020.1713087
(6) Maher, S.; Brayden, D. J.; Casettari, L.; Illum, L. Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. Pharmaceutics 2019, 11 (1), 10.3390/pharmaceutics11010041
(7) Williams, A. C.; Barry, B. W. Penetration enhancers. Adv Drug Deliv Rev 2004, 56 (5), 603-618. 10.1016/j.addr.2003.10.025